Deal Watch: Novartis Opts In On Lipoprotein A Candidate From Akcea
Executive Summary
Novartis will take over development and commercialization of antisense candidate TQJ230 under rights it obtained in a 2017 agreement. Morphic and Janssen will collaborate on oral integrin inhibitors.
You may also be interested in...
Silence Open To A Partner But Ready To Go It Alone On Lp(a) Drug
The company said it has the financing to move forward with a Phase III program for zerlasiran in patients with high lipoprotein(a) at high risk of atherosclerotic cardiovascular disease.
Janssen Follows AbbVie To Exit From Morphic Deal, But Lead Asset Still Has Chance
Morphic said that Janssen had chosen to exit the partnership formed in 2019, just a little more than half a year after AbbVie did the same.
Amgen To Rapidly Move Olpasiran Into Phase III For Lp(a) Reduction
The siRNA drug demonstrated a significant reduction in lipoprotein(a) from baseline of up to or greater than 90% for the majority of doses in a Phase II trial; Novartis has a potential first-to-market advantage.